<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934567</url>
  </required_header>
  <id_info>
    <org_study_id>XYN-605</org_study_id>
    <nct_id>NCT03934567</nct_id>
  </id_info>
  <brief_title>A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma</brief_title>
  <official_title>An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xynomic Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xynomic Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of
      oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with
      relapsed or refractory follicular lymphoma (FL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-arm, two-stage, multi-center, phase 2 study in patients with
      relapsed/refractory follicular lymphoma (FL) who have received at least two prior standard
      therapy lines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effect of abexinostat on objective response rate as assessed by an independent central imaging review</measure>
    <time_frame>up to 56 days</time_frame>
    <description>Objective response rate (ORR), defined as the proportion of patients who have completed response (CR) or partial response (PR) as assessed by an Independent Central Imaging Review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>up to 56 days</time_frame>
    <description>Objective response rate (ORR) as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free survival (PFS), defined as the time from the initiation of treatment to disease progression or death as assessed by the Independent Central Imaging Review and the investigator</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Lymphoma, Follicular</condition>
  <arm_group>
    <arm_group_label>Abexinostat 80 mg bis in die (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Abexinostat 80 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abexinostat</intervention_name>
    <description>Abexinostat tablets</description>
    <arm_group_label>Abexinostat 80 mg bis in die (BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Life expectancy â‰¥ 3 months

          2. Histologically confirmed grade 1, 2, or 3a follicular lymphoma (FL)

          3. Have received at least two prior standard therapy lines including anti- cluster of
             differentiation antigen (anti-CD20) antibody and cytotoxic therapy for follicular
             lymphoma (FL)

          4. Confirmed to be unresponsive to the last line of therapy (have stable disease or
             disease progression during treatment),or have disease progression following the last
             line of therapy

          5. Have at least one radiologically measurable lymph node or extranodal lymphoid
             malignant lesion as assessed by computed tomography (CT) or magnetic resonance imaging
             (MRI);

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          7. Meet various hematological, liver function and renal function lab parameters

        Exclusion Criteria:

          1. Histologically confirmed grade 3b follicular lymphoma, or transformed diffuse large
             B-cell lymphoma (DLBCL)

          2. Current or history of central nervous system (CNS) lymphoma;

          3. Toxicity not yet recovered from previous anti-tumor therapies

          4. Uncontrolled systemic infections or infections requiring intravenous antibiotics

          5. Have previously treated by abexinostat or other histone deacetylase (HDAC) inhibitors;

          6. Have received steroid hormone within 7 days, chemotherapy, targeted therapy within 28
             days, radiotherapy within 14 days, anti-cancer antibody therapies within 28 days

          7. Unable to swallow tablets, or presence of significant functional gastrointestinal
             disorders that may affect the oral administration and absorption of the study drug

          8. Have received autologous stem cell transplant within 3 months before the first dose,
             or allogeneic stem cell transplant within 6 months before the first dose

          9. Presence of active graft-versus-host disease

         10. Have undergone a major surgery within 28 days

         11. Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus
             (HCV) infection

         12. Have cardiac impairment as defined per protocol

         13. Have prior history of malignancies other than follicular lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai SHI, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Zhao, MD</last_name>
    <phone>(01186)13716386801</phone>
    <email>bing.zhao@xynomicpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophia Paspal, Ph.D. RAC</last_name>
    <phone>610-405-5974</phone>
    <email>sophia.paspal@xynomicpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD, PhD</last_name>
      <phone>13701251865</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenling Li, M.M.</last_name>
      <phone>13520114408</phone>
      <email>zryyxy2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital)</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hang Su, M.M.</last_name>
      <phone>13701396736</phone>
      <email>suhang307@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Ke, MD</last_name>
      <phone>13911068649</phone>
      <email>xiaoyank@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng, M.M.</last_name>
      <phone>13943012851</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liqun Zou, MD</last_name>
      <phone>18980601027</phone>
      <email>zliqun@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yajie Gao, M.M.</last_name>
      <phone>15541192088</phone>
      <email>gaoyajie100@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tingbo Liu, PhD</last_name>
      <phone>13365910316</phone>
      <email>13769988835@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuan Jin, M.M.</last_name>
      <phone>13688896983</phone>
      <email>jinchuan5959@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yudan Wu, M.M.</last_name>
      <phone>13857182590</phone>
      <email>haiyanyang1125@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ru Feng, M.M.</last_name>
      <phone>13725119672</phone>
      <email>Ruth1626@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Hainan</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongxia Yao, M.M.</last_name>
      <phone>13876081106</phone>
      <email>yaohongxia768@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medical</name>
      <address>
        <city>Hangzhou</city>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, MD</last_name>
      <phone>0571-86006926</phone>
      <email>shonco@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Yang, MD</last_name>
      <phone>13857182590</phone>
      <email>haiyanyang1125@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, MD</last_name>
      <phone>13313612989</phone>
      <email>sy86298276@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaming Xi, MD</last_name>
      <phone>13919110815</phone>
      <email>xiyaming02@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Wang, M.M.</last_name>
      <phone>15168920632</phone>
      <email>LYSZLYYNSK@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth people's hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkang Chang, MD</last_name>
      <phone>13764643870</phone>
      <email>Changchunkang7010@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junning Cao, M.M.</last_name>
      <phone>13817384270</phone>
      <email>cao_junning@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Forth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuhuan Gao, MD</last_name>
      <phone>13503217908</phone>
      <email>ydsygao@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qinghua Wang, PhD</last_name>
      <phone>18622221223</phone>
      <email>huaqingw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Li, MD</last_name>
      <phone>13852439312</phone>
      <email>frankfeng_2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufu Li, MD</last_name>
      <phone>13598009218</phone>
      <email>liyufu439@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, MD</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>lymph nodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abexinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

